Could simvastatin be a treatment for secondary progressive MS?
In this video, Professor Jeremy Chataway talks about the MS STAT-2 trial and how it could help people with MS.
- Lead researcher:
- Professor Jeremy Chataway
- Based at:
- UCL Institute of Neurology
- MS Society funding:
- £1.17 million
We’re proud to co-fund this phase 3 trial testing if simvastatin can slow progression in secondary progressive MS. If successful, simvastatin could be one of the first treatments licensed for this type of MS.
The MS-STAT2 trial will test if simvastatin can slow disability progression over a three-year period. They will measure progression using the Expanded Disability Status Scale, which assesses changes in walking and other MS symptoms.
The trial began in summer 2017 and involves almost 1000 people with secondary progressive MS. It will take six years to complete and involve over 30 trial centres across the UK.
Recruitment for MS-STAT2 completed in August 2021. The trial will continue for another three years and then there will be a period of data analysis before results are announced.
How will it help people with MS?
Right now there are no treatments that can slow or stop the accumulation of disability associated with MS. If this trial is successful, simvastatin could be one of the first treatments licensed for secondary progressive MS.
The difference you can make
The race is on to find therapies that will slow progression. You can help speed up the process by supporting projects like this.